High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Baumbusch, Lars O ^a   Helland, Åslaug ^a,b   Wang, Yun ^a   Liestøl, Knut ^c   Schaner, Marci E ^d   Holm, Ruth ^e   Etemadmoghadam, Dariush ^f,g   Alsop, Kathryn ^f,g   Brown, Pat ^d   Mitchell, Gillian ^f,g   Fereday, Sian ^f   DeFazio, Anna ^h   Bowtell, David D L ^f,g   Kristensen, Gunnar B ^a   Lingjærde, Ole Christian ^a,c   Børresen Dale, Anne Lise ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUSTRALIA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; COHORT ANALYSIS; COPY NUMBER VARIATION; DISEASE ASSOCIATION; FEMALE; GENOMIC INSTABILITY; HUMAN; MAJOR CLINICAL STUDY; NORWAY; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ADULT; CHROMOSOME ABERRATIONS; CYSTADENOCARCINOMA, SEROUS; CYSTADENOMA, SEROUS; DNA COPY NUMBER VARIATIONS; FEMALE; GENOME; GENOMIC INSTABILITY; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 84872798812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054356     Document Type: Article

References (49)

1. Martin SA, Hewish M, Lord CJ, Ashworth A, (2010) Genomic instability and the selection of treatments for cancer. J Pathol 220: 281-289.
2. Gorringe KL, Campbell IG, (2009) Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 3: 157-164.
3. Kobel M, Huntsman D, Gilks CB, (2008) Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med 10: e22.
4. Lawrenson K, Gayther SA, (2009) Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 6: e25.
5. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, et al. (2005) Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696.
6. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, et al. (2009) Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 15: 2448-2455.
7. Cancer Genome Atlas Research Network, (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
8. Crijns AP, Fehrmann RS, de JS, Gerbens F, Meersma GJ, et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 6: e24.
9. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, et al. (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155.
10. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, et al. (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 6: e18064.
11. Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, et al. (2006) Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 16: 1733-1745.
12. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, et al. (2005) Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918.
13. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, et al. (2011) IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 17: 2538-2548.
14. Caserta D, Benkhalifa M, Baldi M, Fiorentino F, Qumsiyeh M, et al. (2008) Genome profiling of ovarian adenocarcinomas using pangenomic BACs microarray comparative genomic hybridization. Mol Cytogenet 20 1: 10.
15. Dimova I, Orsetti B, Negre V, Rouge C, Ursule L, et al. (2009) Genomic markers for ovarian cancer at chromosomes 1, 8 and 17 revealed by array CGH analysis. Tumori 95: 357-366.
16. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, et al. (2011) Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17: 1521-1534.
17. Bruchim I, Israeli O, Mahmud SM, Viram-Goldring A, Rienstein S, et al. (2009) Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma. Cancer Genet Cytogenet 190: 66-70.
18. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, et al. (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10: 1251-1256.
19. Helou K, Padilla-Nash H, Wangsa D, Karlsson E, Osterberg L, et al. (2006) Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors. Cancer Genet Cytogenet 170: 1-8.
20. Mayr D, Kanitz V, Anderegg B, Luthardt B, Engel J, et al. (2006) Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays. Am J Clin Pathol 126: 101-109.
21. Nowee ME, Snijders AM, Rockx DA, de Wit RM, Kosma VM, et al. (2007) DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification. J Pathol 213: 46-55.
22. Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, et al. (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE 6: e28503.
23. Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA, (2011) Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin Cancer Res 17: 7704-7711.
24. M'kacher R, Andreoletti L, Flamant S, Milliat F, Girinsky T, et al. (2010) JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin's lymphoma patients and poor clinical outcome. Ann Oncol 21: 826-832.
25. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, et al. (2009) Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A 106: 7131-7136.
26. Janssen A, Kops GJ, Medema RH, (2009) Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 106: 19108-19113.
27. Kops GJ, Foltz DR, Cleveland DW, (2004) Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 101: 8699-8704.
28. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, et al. (2011) Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 71: 3447-3452.
29. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, et al. (2011) Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 20: 2183-2194.
30. Birkbak NJ, Wang ZC, Kim J-Y, Eklund AC, Li Q, et al. (2012) Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discovery DOI:10.1158/2159-8290.CD-11-0206: 367-375.
31. Berwick M, Vineis P, (2005) Measuring DNA repair capacity: small steps. J Natl Cancer Inst 19 97: 84-85.
32. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, et al. (2004) Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24: 21-34.
33. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, et al. (2009) Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427.
34. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
35. Baumbusch LO, Aarøe J, Johansen FE, Hicks J, Sun H, et al. (2008) Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. BMC Genomics 9: 379.
36. Lingjærde OC, Baumbusch LO, Liestøl K, Glad IK, Børresen-Dale AL, (2005) CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 21: 821-822.
37. Russnes HG, Vollan HK, Lingjørde OC, Krasnitz A, Lundin P, et al. (2010) Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2: 38ra47.
38. Eide MB, Liestøl K, Lingjærde OC, Hystad ME, Kresse SH, et al. (2010) Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood 116: 1489-1497.
39. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, et al. (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive woman with ovarian cancer: a report rrom the Australian Ovarian Cancer Study Group. J Clin Oncol. zdoi;10.1200/JCO.2011.39.8545.
40. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, et al. (2010) Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 5: e11408.
41. Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, et al. (2011) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118: 3703-3709.
42. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, et al. (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306: 1557-1565.
43. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, et al. (2011) Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS ONE 6: e28250.
44. McClelland SE, Burrell RA, Swanton C, (2009) Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 8: 3262-3266.
45. Rao CV, Yamada HY, Yao Y, Dai W, (2009) Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis 30: 1469-1474.
46. Thompson SL, Bakhoum SF, Compton DA, (2010) Mechanisms of chromosomal instability. Curr Biol 20: R285-R295.
47. Lord CJ, Ashworth A, (2012) The DNA damage response and cancer therapy. Nature 481: 287-294.
48. Berwick M, Vineis P, (2005) Measuring DNA repair capacity: small steps. J Natl Cancer Inst 19 97: 84-85.
49. Vollebergh MA, Jonkers J, Linn SC, (2012) Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. Cell Mol Life Sci 69: 223-245.